Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votes
GovInfo API
Floor speeches, reports, bill text
Federal Election Commission (FEC)
Campaign finance
VoteView (UCLA)
Ideology scores (DW-NOMINATE)
GovTrack.us
Misconduct data (CC0)
U.S. Census Bureau
District demographics

Data Last Updated

Bills & Votes: 5 hours ago
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

HR1082Passed House

Shandra Eisenga Human Cell and Tissue Product Safety Act

Share:
Introduced
In Committee
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-02-06
Introduced
1
Cosponsors
HR
ⓘ
Type

Sponsor

John R. Moolenaar
John R. Moolenaar
Republican · MI · Representative
Votes with party: 98.2% (606 recorded votes)

Full profile: /officials/M001194

Source: Congress.gov · FEC

Cosponsors (1)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

1 cosponsor on record at Congress.gov. The named list is syncing into Govwatch and will appear here shortly — view on Congress.gov in the meantime.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

2025-06-24

Source: Congress.gov

Committee Activity

Currently in

  • Senate Committee on Health, Education, Labor, and PensionsReferred To · 2025-06-24
  • House Committee on Energy and CommerceReported By · 2025-06-12

Previously

  • House Committee on Energy and CommerceMarkup By · 2025-04-29
  • House Committee on Energy and CommerceReferred To · 2025-02-06

Plain-English Summary

Shandra Eisenga Human Cell and Tissue Product Safety Act This bill establishes civil penalties for violations of regulations governing the donation and handling of human cell and tissue products. It also requires the Food and Drug Administration (FDA) to report on the regulation of these products and to provide related information to stakeholders. ( Human cell and tissue products are articles containing or consisting of human cells or tissues that are intended for use in a human recipient.) Specifically, the bill establishes civil penalties for violations of the FDA’s regulations on donor eligibility and current good tissue practice for manufacturing and distributing human cell and tissue products. Also, the bill requires the FDA to conduct workshops to educate stakeholders and facilitate discussion on the science and regulation of human cell and tissue products. The FDA must establish a public docket to receive written comments on this topic, and report to Congress with recommendations. The bill also requires the FDA to support the development of educational materials for health care professionals regarding organ, tissue, and eye donations and related topics. Additionally, the bill requires the FDA to publish on its website educational materials about the Tissue Reference Group (a working group within the FDA) and best practices for obtaining a recommendation from them about human cell and tissue products. Also, annually for three years, the FDA must publish on its website information on inquiries submitted to the Tissue Reference Group and FDA registrations and inspections regarding human cell and tissue manufacturers.

Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.

  • HR9711Autocycle Safety Act
    Referred to Committee · 2026-07-15
  • HR9642Medicare Access to Rural Anesthesiology Act
    Referred to Committee · 2026-07-15
  • HR3194LOCOMOTIVES Act
    Referred to Committee · 2026-07-14
  • HR2306Adams Memorial-Great American Heroes Act
    Passed House · 2026-07-13